Trial Profile
A Dose-escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA, ZolinzaTM) in Combination With Capecitabine (XelodaTM) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 01 Mar 2017 This study was originally intended to be a phase 1/phase 2. The protocol was amended to make this study a phase 1 only.
- 01 Mar 2017 Status changed from recruiting to completed.
- 09 Sep 2013 Results presented at the 2013 Breast Cancer Symposium.